{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TVGNW"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"TVGNW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVGNW\",,,,,undefined,":{"symbol":"TVGNW","market":"US","secType":"STK","nameCN":"Tevogen Bio Holdings Inc.","latestPrice":0.0579,"timestamp":1743192000000,"preClose":0.0579,"halted":0,"volume":307087,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":0,"latestTime":"03-28 16:00:00 EDT","open":0.0495,"high":0.05799,"low":0.0444,"amount":15313.50763,"amplitude":0.234715,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743408000000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.0579,"volumeRatio":1.024023},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVGNW\",,,,,undefined,":{"symbol":"TVGNW","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.024023,"shares":0,"dividePrice":0,"high":0.05799,"amplitude":0.234715,"preClose":0.0579,"low":0.0444,"week52Low":0.0099,"pbRate":"--","week52High":0.1499,"institutionHeld":0,"latestPrice":0.0579,"eps":0,"divideRate":0,"volume":307087,"delay":0,"ttmEps":0,"open":0.0495,"prevYearClose":0.054,"prevWeekClose":0.0544,"prevMonthClose":0.0669,"prevQuarterClose":0.054,"fiveDayClose":0.0544,"twentyDayClose":0.0669,"sixtyDayClose":0.0628},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/TVGNW\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TVGNW\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2518208975","title":"BRIEF-Tevogen Bio Announces Unique T Cell Vaccine Under Development & Files Patent With USPTO","url":"https://stock-news.laohu8.com/highlight/detail?id=2518208975","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518208975?lang=en_us&edition=fundamental","pubTime":"2025-03-11 01:06","pubTimestamp":1741626362,"startTime":"0","endTime":"0","summary":"BRIEF-Tevogen Bio Announces Unique T Cell Vaccine Under Development & Files Patent With USPTOMarch 10 (Reuters) - Tevogen Bio Holdings Inc TVGN.O:TEVOGEN BIO ANNOUNCES UNIQUE T CELL VACCINE UNDER DEVE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nTUABD34QV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGN","TVGNW"],"gpt_icon":0},{"id":"2518270844","title":"Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent With the Uspto","url":"https://stock-news.laohu8.com/highlight/detail?id=2518270844","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518270844?lang=en_us&edition=fundamental","pubTime":"2025-03-11 00:40","pubTimestamp":1741624832,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250310:nTUABD34QV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","BK4139","TVGNW"],"gpt_icon":0},{"id":"2518270671","title":"Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO","url":"https://stock-news.laohu8.com/highlight/detail?id=2518270671","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518270671?lang=en_us&edition=fundamental","pubTime":"2025-03-11 00:40","pubTimestamp":1741624800,"startTime":"0","endTime":"0","summary":"Vaccine is intended to stimulate T cell responses against targets across the entire genome of the selected virus, similar to company’s lead product candidate TVGN 489, to mitigate the risk posed by mutations.Approach may provide prophylaxis to viral infections and would be complementary to current treatment under development by Tevogen Bio.Powered by Tevogen Bio’s artificial intelligence initiative, Tevogen.AI.The company hopes to address public concerns about inoculation during vaccine development.Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations. Tevogen Bio leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibilit","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bio-announces-unique-t-164000928.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","TVGN","TVGNW"],"gpt_icon":0},{"id":"2510581991","title":"Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2510581991","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510581991?lang=en_us&edition=fundamental","pubTime":"2025-02-11 06:30","pubTimestamp":1739226600,"startTime":"0","endTime":"0","summary":"WARREN, N.J., Feb. 10, 2025  -- Tevogen Bio  , is a clinical-stage specialty immunotherapy biotech company. As the biopharma industry faces increasing competition from international markets and an evolving regulatory landscape, Tevogen Bio’s innovative business model positions it as a potential leader in the shift towards cost-efficient, value-driven healthcare.With the concern of Chinese pharmaceutical companies developing drugs at a faster pace and lower cost, the U.S. biotech sector faces pressure to adapt. At the same time, Robert F. Kennedy Jr., who is soon to helm the Department of Health and Human Services, has prioritized affordable healthcare, prompting industry-wide discussions on sustainability and access. Built with these industry themes in mind, Tevogen Bio exemplifies how American biotech can remain competitive and thrive amid growing concerns surrounding affordability, efficiency, and global competition.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bios-business-model-addresses-223000195.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TVGNW","TVGN","BK4139"],"gpt_icon":0}],"pageSize":4,"totalPage":8,"pageCount":1,"totalSize":32}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TVGNW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-02-15","symbol":"TVGNW","reason":null,"defaultRemindTime":1708007400000,"announcedDate":"2024-02-14","type":"delisting","dateTimestamp":1707973200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TVGNW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TVGNW\",market:\"US\",delay:false,,,undefined,":{}}}